News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
278,975 Results
Type
Article (15039)
Company Profile (281)
Press Release (263655)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (81425)
Career Advice (170)
Deals (13520)
Drug Delivery (36)
Drug Development (52081)
Employer Resources (35)
FDA (6279)
Job Trends (5524)
News (149006)
Policy (10554)
Tag
Academia (965)
Accelerated approval (2)
Adcomms (12)
Allergies (55)
Alliances (22104)
ALS (69)
Alzheimer's disease (878)
Antibody-drug conjugate (ADC) (108)
Approvals (6309)
Artificial intelligence (139)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4961)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (64)
Brain cancer (20)
Breast cancer (168)
Cancer (1569)
Cardiovascular disease (124)
Career advice (149)
Career pathing (2)
CAR-T (125)
Cell therapy (345)
Cervical cancer (12)
Clinical research (42666)
Collaboration (566)
Compensation (281)
Complete response letters (13)
COVID-19 (1085)
CRISPR (45)
C-suite (173)
Cystic fibrosis (79)
Data (1674)
Denatured (11)
Depression (32)
Diabetes (145)
Diagnostics (1406)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (90)
Drug pricing (30)
Drug shortages (3)
Duchenne muscular dystrophy (92)
Earnings (31313)
Editorial (19)
Employer branding (5)
Employer resources (32)
Events (49801)
Executive appointments (481)
FDA (7093)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (522)
Gene editing (103)
Generative AI (11)
Gene therapy (267)
GLP-1 (377)
Government (1151)
Grass and pollen (2)
Guidances (80)
Healthcare (6949)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (100)
Indications (21)
Infectious disease (1153)
Inflammatory bowel disease (123)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (70)
Interviews (20)
IPO (7449)
IRA (11)
Job creations (877)
Job search strategy (137)
Kidney cancer (7)
Labor market (9)
Layoffs (220)
Leadership (4)
Legal (1435)
Liver cancer (36)
Lung cancer (214)
Lymphoma (104)
Machine learning (5)
Management (8)
Manufacturing (150)
MASH (63)
Medical device (3030)
Medtech (3031)
Mergers & acquisitions (6417)
Metabolic disorders (414)
Multiple sclerosis (54)
NASH (14)
Neurodegenerative disease (75)
Neuropsychiatric disorders (25)
Neuroscience (1310)
NextGen: Class of 2025 (2092)
Non-profit (896)
Now hiring (22)
Obesity (201)
Opinion (107)
Ovarian cancer (68)
Pain (48)
Pancreatic cancer (62)
Parkinson's disease (125)
Partnered (8)
Patents (141)
Patient recruitment (86)
Peanut (36)
People (25927)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14752)
Phase II (19687)
Phase III (12823)
Pipeline (966)
Policy (50)
Postmarket research (985)
Preclinical (6214)
Press Release (31)
Prostate cancer (66)
Psychedelics (35)
Radiopharmaceuticals (215)
Rare diseases (304)
Real estate (1451)
Recruiting (14)
Regulatory (9126)
Reports (17)
Research institute (981)
Resumes & cover letters (20)
Rett syndrome (5)
RNA editing (5)
RSV (10)
Schizophrenia (64)
Series A (102)
Series B (70)
Service/supplier (1)
Sickle cell disease (43)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (13)
Startups (2006)
State (1)
Stomach cancer (4)
Supply chain (24)
Tariffs (12)
The Weekly (37)
Vaccines (234)
Venture capitalists (32)
Weight loss (113)
Women's health (17)
Worklife (3)
Date
Today (75)
Last 7 days (646)
Last 30 days (1959)
Last 365 days (19779)
2025 (7293)
2024 (21078)
2023 (23028)
2022 (27669)
2021 (28682)
2020 (24162)
2019 (17002)
2018 (12401)
2017 (14358)
2016 (12424)
2015 (14906)
2014 (10792)
2013 (7795)
2012 (7842)
2011 (7990)
2010 (7759)
Location
Africa (157)
Alabama (43)
Alaska (2)
Arizona (54)
Arkansas (5)
Asia (17900)
Australia (3030)
California (4158)
Canada (1200)
China (382)
Colorado (155)
Connecticut (160)
Delaware (122)
Europe (38508)
Florida (524)
Georgia (126)
Idaho (18)
Illinois (246)
India (10)
Indiana (106)
Iowa (2)
Japan (86)
Kansas (64)
Kentucky (6)
Louisiana (3)
Maine (11)
Maryland (508)
Massachusetts (3301)
Michigan (76)
Minnesota (159)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (18)
New Jersey (1062)
New Mexico (12)
New York (1108)
North Carolina (577)
North Dakota (5)
Northern California (1859)
Ohio (119)
Oklahoma (9)
Oregon (21)
Pennsylvania (788)
Puerto Rico (6)
Rhode Island (19)
South America (218)
South Carolina (5)
Southern California (1590)
Tennessee (29)
Texas (509)
United States (14300)
Utah (58)
Virginia (84)
Washington D.C. (31)
Washington State (374)
Wisconsin (19)
278,975 Results for "frequency therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
April 14, 2025
·
5 min read
Lone Star Bio
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 11,872,397 relating to the Company’s non-invasive, frequency-based deep brain stimulation device.
January 23, 2024
·
4 min read
Lone Star Bio
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
Nexalin Technology, Inc. announced that the United States Patent and Trademark Office has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.
June 20, 2024
·
4 min read
Press Releases
FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency in ctDNA of 85% of Patients
April 25, 2025
·
5 min read
Deals
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Korro Bio, Inc. and Frequency Therapeutics, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
July 14, 2023
·
18 min read
Lone Star Bio
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 17/337,653 relating to the Company’s non-invasive, frequency-based deep brain stimulation device.
April 4, 2024
·
3 min read
Deals
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Korro Bio, Inc. announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio, Inc.
November 3, 2023
·
9 min read
Deals
UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Korro Bio, Inc. announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio, Inc.
November 3, 2023
·
9 min read
Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause
Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms associated with menopause compared to placebo.
May 16, 2024
·
11 min read
Press Releases
Gynesonics Announces New York Medicaid Coverage for CPT Code 58580, Transcervical Radio Frequency Ablation of Uterine Fibroids
December 18, 2024
·
2 min read
1 of 27,898
Next
